LP-184 by Starlight Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Alterome raises $132M to take next-gen cancer drugs aimed at the ‘undruggable’ into clinic

With a new $132 million in hand, Alterome Therapeutics is finally divulging what it’s working on. The oncology company will be using its Series B

April 4, 2024

Galenica continues to grow in the 2023 financial year – Biotech Investments

Galenica AG / Key word(s): Annual Results 12-March-2024 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

March 13, 2024

EC approves Novartis’ Kisqali for early breast cancer treatment

November 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.